Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is projected to declare fiscal fourth quarter financial results right before the stock market’s official open on February 28, 2017. The stock added about 100.9 percent in price since last results when it was at $1.17 a share. Based on the most relevant past-periods data, there is an 57.14 percent probability for this firm’s share price to go down following next quarterly results. Earnings reaction history tells us that the equity price moved down 16 times out of last 28 reported quarters. It has beaten earnings-per-share estimates 83% of the time in its last 12 earnings reports. It fell short of earnings estimates on 2 occasions, and it has met expectations 0 time.
Here’s how traders responded to INFI earnings announcements over the past few quarters.
Infinity Pharmaceuticals, Inc. (INFI) Earnings Surprises & Reaction
Given its history, the average earnings announcement surprise was 28.38 percent over the past four quarters. Back on November 9, 2016, it posted earnings per-share earnings at $-0.39 which beat the consensus $-0.84 projection (positive surprise of53.57%. For the quarter, revenue came in at 0M versus consensus estimate of 7.27M. The stock gained 9.4 percent the session following the earnings reports were released, and on 7th day price change was 3.42 percent.
On August 9, 2016, it reported earnings at $-0.43 a share compared with the consensus estimate of $-0.89 per share (positive surprise of 51.69%). Revenue of 9.47M for that quarter was above the $13.91M analysts had expected. The stock retreated -6.21% the day following the earnings announcement, and on 7th day price change was 1.86%.
On May 4, 2016, it recorded $-0.82 a share in earnings which topped the consensus estimate of $-0.86 (positive surprise of 4.65%). Revenue for the quarter was $9.26M while analysts called for revenues to be $8.8M. The stock dropped -6.07% the day following the earnings data was made public, and on 7th day price change was -9.38%.
On February 23, 2016, it announced earnings per share at $-0.8 versus the consensus estimate of $-0.83 per share (positive surprise of 3.61%). That came on revenues of $9.08M for that period. Analysts had expected $18.26M in revenue.
Infinity Pharmaceuticals, Inc. Earnings Estimates
As Q4 earnings announcement date approaches, Wall Street is expecting earnings per share of $-0.24. The analysts’ present consensus range is $-0.24-$-0.24 for EPS. The market consensus range for revenue is between $58.8M and $58.8M, with an average of $58.8M.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) last ended at $2.33, sending the company’s market cap near $115.87M. The consensus 12-month price target from analysts covering the stock is $2. The share price has declined -66.57% from its top level in 52 weeks and dropped 72.59% this year. It recently traded in a range of $2.25-$2.43 at a volume of 772786 shares. The recent trading ended with the price nearly -7.17 lower for the last 5 trading days, rebounding 177.38% from its 52-week low.